Compare ELME & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELME | ELDN |
|---|---|---|
| Founded | 1960 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 229.3M |
| IPO Year | 1994 | 2014 |
| Metric | ELME | ELDN |
|---|---|---|
| Price | $2.04 | $3.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $12.67 | $8.50 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 741.95% | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $206,360,000.00 | N/A |
| Revenue This Year | $5.03 | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.98 | $1.35 |
| 52 Week High | $17.68 | $4.60 |
| Indicator | ELME | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 23.19 | 60.69 |
| Support Level | $1.98 | $2.48 |
| Resistance Level | $2.26 | $3.17 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 29.63 | 70.83 |
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.